Research led by Indiana University School of Medicine and the University of Notre Dame shows a new treatment for peanut allergy is effective in a mouse model. The therapy, a covalent heterobivalent inhibitor, differs from most allergy treatments in that it is more of a preventative therapy rather than a drug to treat immediate acute symptoms. “Essentially, in the model, we can treat once and then the mice seem to be protected for several weeks from challenge with peanut,” lead researcher Mark Kaplan, a professor at Indiana University School of Medicine, told BioWorld. Read More

While the new inflation-based rebate on certain Part B drugs may generate billions of dollars in savings for Medicare, implementing the rebate could be more challenging than the U.S. Congress and the Biden administration expected when the Inflation Reduction Act was enacted last August. Read More

In its first worldwide licensing deal in the cardiovascular space, Ji Xing Pharmaceuticals Ltd. acquired rights to preclinical-stage PB-6440, in development for diseases including hypertension, from Phasebio Pharmaceuticals Inc. Read More

The U.S. International Trade Commission (USITC) is launching an investigation into the importation from China of certain thyroid hormone receptor-beta agonists, products containing them and the manufacturing processes being used. Read More

A federal court cut off efforts Feb. 6 to halt a U.S. program allowing prescription drug imports from Canada before the program gets off the ground. The U.S. District Court for the District of Columbia dismissed a suit by the Pharmaceutical Research and Manufacturers of America (PhRMA) and other organizations, saying that they lacked standing because neither they nor their members face “a concrete risk of harm from the inchoate importation program.” Read More

New hires and promotions in the biopharma industry, including: Allosteric, Carisma, Cour, Enplusone, Immpact, Immunome, Larimar, Merck, Micurx, Moma, Ovid, Palisade, T-knife. Read More

Biopharmas raising money in public or private financings, including: Cellectis, Curevac, Fortress, Kinsea, Longboard, Mediwound, Relief, Sonnet, Structure. Read More

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve, CNS, Geovax, Immix, Innocare, Neuron23, Onconova, Osteal, Roche, TC. Read More

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AC Immune, Ankyra, Eumentis, Inmune, J&J, Merck & Co., Nectin, Thermo, Wellmarker. Read More

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aldeyra, Awakn, Astrazeneca, CSL Vifor, FSD, Kiora, Optimi, Pharmather, Rocket. Read More